Saturday 17 October 2026
Export CCEL’s income statement to Excel — free account
Cryo-Cell International Inc.
CCEL Healthcare Medical Care Facilities
Cryo-Cell International Inc.’s revenue for fiscal 2025 (year ended November 2025) was $31.6 million, down 1.31% from fiscal 2024. In the quarter to August 2026, revenue was flat, EPS grew 77.8%, free cash flow fell 58.4% and total debt fell 29.5%, each against the same quarter a year earlier.
4.42
0.77
+21.10%
Follow CCEL
| Nov '16 | Nov '17 | Nov '18 | Nov '19 | Nov '20 | Nov '21 | Nov '22 | Nov '23 | Nov '24 | Nov '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 24.42 | 0.00 | 26.32 | 15.96 | 47.62 | 12.85 | 0.00 | 170.80 | 0.00 |
Piotroski F-Score |
4 | 7 | 3 | 6 | 8 | 4 | 5 | 6 | 9 | 6 |
P/S ratio |
1.49 | 2.24 | 1.87 | 1.85 | 1.82 | 3.49 | 1.22 | 1.42 | 2.17 | 1.02 |
Altman Z-Score |
(0.32) | 1.20 | 0.88 | 1.11 | 1.40 | 1.27 | 0.36 | (0.72) | 0.34 | (0.23) |
Altman Z″-Score (non-manufacturers) |
(6.16) | (2.62) | (1.41) | (1.07) | 0.03 | (0.95) | (1.69) | (4.39) | (2.39) | (3.07) |
P/FCF ratio |
7.42 | 10.13 | 11.66 | 10.83 | 7.06 | 103.33 | 0.00 | 34.84 | 32.44 | 8.24 |
Beneish M-Score |
(4.04) | (2.68) | (2.72) | (2.80) | (2.94) | (2.97) | (2.70) | (3.90) | (2.75) | (3.17) |
P/Operating CF |
13.45 | 26.96 | 64.73 | 52.34 | 19.01 | 60.41 | 15.23 | 13.34 | 32.19 | 25.07 |
Dividend Safety Score |
— | — | — | — | — | — | — | — | — | 20 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.07 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
1.65 | 2.19 | 1.97 | 1.80 | 1.68 | 3.30 | 1.52 | 1.70 | 2.43 | 1.24 |
EV/EBITDA |
13.84 | 10.35 | 10.25 | 10.27 | 6.24 | 17.63 | 7.89 | 0.00 | 17.19 | 20.99 |
EV/Operating CF |
7.65 | 9.71 | 10.79 | 9.10 | 6.18 | 12.01 | 5.38 | 5.98 | 12.94 | 7.17 |
EV/FCF |
8.22 | 9.88 | 12.28 | 10.54 | 6.53 | 97.67 | (6.86) | 41.61 | 36.33 | 10.08 |
Quick Ratio |
0.62 | 0.85 | 0.83 | 0.88 | 1.02 | 0.65 | 0.40 | 0.36 | 0.50 | 0.51 |
Current Ratio |
0.69 | 0.91 | 0.96 | 1.00 | 1.13 | 0.75 | 0.49 | 0.45 | 0.58 | 0.59 |
Net Debt/EBITDA |
2.07 | 0.11 | 1.07 | 0.27 | (0.50) | (1.02) | 1.56 | (0.82) | 1.84 | 3.83 |
Debt/Assets |
50.26% | 30.51% | 30.53% | 20.88% | 13.46% | 4.65% | 16.73% | 15.77% | 18.29% | 16.96% |
Debt/Equity |
(0.64) | (0.58) | (1.45) | (1.29) | (2.33) | 0.67 | (7.12) | (0.87) | (0.90) | (0.56) |
Asset Turnover |
1.18 | 1.17 | 0.88 | 0.75 | 0.70 | 0.54 | 0.48 | 0.50 | 0.51 | 0.50 |
Operating CF/Net income |
(3.78) | 2.47 | (6.24) | 2.75 | 2.34 | 3.80 | 3.09 | (0.94) | 14.95 | (2.26) |
Capex/Depreciation |
(0.15) | (0.28) | (1.51) | (1.29) | (0.62) | (5.03) | (8.38) | (4.41) | (3.46) | (0.08) |
Interest Coverage |
0.46 | 3.84 | 3.35 | 2.97 | 4.96 | 2.91 | 2.64 | (9.95) | 1.87 | 0.23 |
| 12.96% | (16.59%) | 7.98% | (28.89%) | (75.37%) | 274.29% | 208.38% | 151.67% | (3.32%) | 15.27% | |
| (6.77%) | 10.66% | (2.58%) | 5.37% | 8.14% | 3.90% | 4.41% | (15.10%) | 0.64% | (3.84%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 33.07% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
42.33% | (722.11%) | (103.79%) | 126.94% | 95.83% | (101.10%) | 74.26% | (99.33%) | 3.13% | (18.69%) |
Average Days of Receivables |
63.96 | 73.70 | 73.29 | 69.95 | 74.10 | 66.38 | 72.72 | 76.58 | 83.41 | 79.16 |
Research and Development Expense of Revenue |
0.23% | 0.16% | 0.31% | 0.09% | 0.08% | 0.17% | 1.27% | 3.74% | 3.88% | 1.19% |
Selling, General and Administrative Expense of Revenue |
63.66% | 53.11% | 53.50% | 46.80% | 45.89% | 50.58% | 51.36% | 54.77% | 57.91% | 57.72% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.08 | 0.07 | 0.08 | 0.30 | 0.26 | 0.05 | 0.04 | 0.05 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.75) | (0.42) | (0.67) | (0.59) | (0.54) | (0.40) | (1.54) | (1.41) | (0.94) | (2.14) |
Graham Number |
2.95 | 0.00 | 1.94 | 0.00 | 0.00 | 1.73 | 0.00 | 5.82 | 0.00 | 4.01 |
Earnings Yield |
(4.79%) | 4.09% | (1.91%) | 3.80% | 6.27% | 2.10% | 7.78% | (21.31%) | 0.59% | (7.79%) |
Free Cash Flow Yield |
13.47% | 9.87% | 8.58% | 9.23% | 14.17% | 0.97% | (18.18%) | 2.87% | 3.08% | 12.13% |
Revenue per Share |
2.85 | 3.59 | 3.92 | 4.08 | 4.13 | 3.55 | 3.58 | 3.76 | 3.93 | 3.91 |
Operating CF per Share |
0.61 | 0.81 | 0.71 | 0.81 | 1.12 | 0.97 | 1.01 | 1.07 | 0.74 | 0.68 |
Capex per Share |
(0.04) | (0.01) | (0.09) | (0.08) | (0.06) | (0.85) | (1.81) | (0.92) | (0.44) | (0.01) |
Free Cash Flow per Share |
0.57 | 0.80 | 0.63 | 0.72 | 1.06 | 0.12 | (0.79) | 0.15 | 0.30 | 0.66 |
Cash per Share |
0.51 | 0.95 | 0.93 | 0.96 | 1.39 | 1.02 | 0.20 | 0.12 | 0.43 | 0.41 |
Shareholders Equity per Share |
(1.90) | (1.77) | (1.19) | (0.89) | (0.35) | 0.51 | (0.18) | (1.32) | (1.63) | (2.31) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.90) | (1.77) | (1.19) | (0.89) | (0.35) | 0.51 | (0.18) | (1.32) | (1.63) | (2.31) |
Free Cash Flow |
4.65 | 5.62 | 4.69 | 5.63 | 8.02 | 0.97 | (6.73) | 1.28 | 2.41 | 5.36 |
Working Capital |
(4.10) | (1.20) | (0.67) | (0.04) | 2.14 | (5.29) | (9.87) | (11.41) | (9.04) | (8.03) |
Capital Expenditures |
(0.34) | (0.10) | (0.65) | (0.66) | (0.45) | (6.95) | (15.30) | (7.64) | (3.60) | (0.12) |
Net Current Asset Value |
(25.94) | (23.68) | (36.54) | (34.45) | (30.31) | (40.70) | (56.80) | (62.80) | (65.34) | (68.58) |
EV/EBIT |
88.04 | 11.09 | 11.09 | 11.31 | 6.83 | 23.70 | 11.46 | 0.00 | 22.35 | 81.46 |
Capex to Sales |
0.01 | 0.00 | 0.02 | 0.02 | 0.01 | 0.24 | 0.50 | 0.24 | 0.11 | 0.00 |
Price to Operating Income |
79.52 | 11.37 | 10.53 | 11.62 | 7.38 | 25.07 | 9.19 | 0.00 | 19.95 | 66.58 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
2.37 | 0.40 | 0.29 | 0.28 | 0.44 | 0.43 | 0.13 | 0.08 | 0.05 | 0.07 |
Cash ROIC |
(315.90%) | 371.98% | 42.80% | 59.61% | 57.26% | 6.35% | (60.87%) | (321.65%) | 114.08% | (110.81%) |
Accounts Receivable Turnover |
6.50 | 5.53 | 5.32 | 5.32 | 5.02 | 4.99 | 5.37 | 4.97 | 4.61 | 4.46 |
Accounts Payable Turnover |
4.10 | 3.94 | 5.35 | 7.63 | 8.30 | 7.35 | 5.68 | 3.51 | 3.14 | 3.10 |
Inventory Turnover |
13.80 | 19.90 | 10.84 | 8.56 | 9.60 | 9.73 | 9.92 | 10.36 | 11.14 | 13.83 |
Average Days of Payables |
93.89 | 104.68 | 53.93 | 49.79 | 36.18 | 60.49 | 66.64 | 138.10 | 86.44 | 142.05 |
Days of Inventory on Hand |
22.82 | 17.08 | 53.88 | 39.44 | 35.05 | 37.40 | 35.34 | 33.45 | 30.20 | 20.23 |
Average Receivables |
3.56 | 4.59 | 5.50 | 5.98 | 6.21 | 5.79 | 5.65 | 6.31 | 6.94 | 7.08 |
Average Payables |
1.41 | 1.71 | 1.60 | 1.32 | 1.16 | 1.22 | 1.55 | 2.39 | 2.53 | 2.38 |
Average Inventory |
0.42 | 0.34 | 0.79 | 1.17 | 1.01 | 0.92 | 0.89 | 0.81 | 0.71 | 0.53 |
Average Assets |
19.52 | 21.72 | 33.15 | 42.64 | 44.54 | 53.43 | 62.78 | 63.05 | 62.95 | 63.20 |
Average Common Equity |
(10.19) | (13.96) | (10.71) | (7.93) | (4.81) | 0.76 | 1.33 | (6.28) | (12.12) | (15.91) |
Columns are period end dates · fundamentals updated 15 Oct 2026